• MPNRF | July 6, 2020

    The MPN Research Foundation is reaching out to the MPN patient community to raise awareness about an opportunity for patients 18 years of age or older with primary myelofibrosis (PMF) or polycythemia vera (PV). Patients who qualify can support research by providing a one-time blood donation from home. The blood sample will be collected by a mobile medical professional staffed by Sanguine Biosciences at a mutually convenient time, and compensation of a $50 gift card will be provided.

    The goal is to collect samples from 50 PMF and PV patients for research to be conducted by Incyte Corporation relating to MPNs. This will include genomic studies allowing scientists to more deeply understand the functions of genes in relation to these diseases and assist researchers in developing new treatments.

    With the growing concern regarding the spread of COVID-19, all mobile medical professionals will be provided personal protective equipment (PPE), including gowns, face masks, gloves, hand sanitizer, and alcohol wipes to protect our participants and staff against the spread of the virus.

    You may qualify to participate if you:
    Are 18 years of age or over
    • Live in the U.S.
    • Have been diagnosed with Myeloproliferative Neoplasms (Primary Myelofibrosis [PMF] or Polycythemia Vera [PV])

    To learn more or sign up call (818) 804-2462 to speak with a research coordinator or click the button below.


    What is preclinical research?
    In preclinical research, researchers test their theories on human samples like blood rather than human participants. This phase helps researchers determine the safest and most effective way to move forward with their project and often helps define the parameters of future clinical trials.

    How will my blood donation help?
    Researchers will always rely on samples from the patient population that they are researching to perform their preclinical research. Your blood is special. It is the key to new therapies and diagnostics. Without it, researchers cannot move forward with their clinical tests, and research projects are stalled or put on hold.